Categories Health Care, Research Summary
Bausch Health Companies Inc. (BHC) stock research summary | Q3 2021
Bausch Health (NYSE: BHC) was negatively impacted by the COVID-19 pandemic as most of its products are dependent on elective medical procedures or patient choices. Sales of its contact lenses dipped amid pandemic-related restrictions as did revenue from medical devices and surgical systems as surgeries and medical procedures were deferred.
The trends have improved since then as restrictions eased and the company is seeing a recovery in its business, which was evident in its third quarter 2021 performance. However, there are still some risks that persist. Take a look at this report to get an idea of the areas where Bausch sees opportunities for growth and which factors are likely to impact its performance in the near term.
The Bausch Health Companies market research report covers key aspects about the firm including company profile, financial highlights and recent key developments. The report is meant as a resource for investors to form a 360 degree understanding about the firm.
Table of Contents
- Overview
- Financial Highlights
- Outlook
- SWOT Analysis
- Business Segment Analysis
- Strategic Drivers
- Competitors
- Key Stock Holders
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
Most Popular
Broadcom (AVGO) thrives on growing AI business. Is the stock a buy?
Broadcom, Inc. (NASDAQ: AVGO), a leading provider of semiconductor solutions for wired and wireless communications, recently impressed the market with upbeat financial outlook highlighting strong prospects for its AI business
After a weak first half, will NIKE (NKE) hit the recovery path this year?
After a prolonged slowdown, NIKE, Inc. (NYSE: NKE) is working on a turnaround plan to regain the brand’s strength. In recent years, the sneaker giant’s overall performance has not been
Lennar (LEN): Even the best-laid plans can go wrong
Shares of Lennar Corporation (NYSE: LEN) stayed green on Monday. The stock has dropped 25% over the past three months. The homebuilder delivered underwhelming results for the fourth quarter of
